Comparative Pharmacology
Head-to-head clinical analysis: IMPAVIDO versus SATRIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IMPAVIDO versus SATRIC.
IMPAVIDO vs SATRIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Miltefosine, the active ingredient in IMPAVIDO, is an alkylphosphocholine with antileishmanial activity. It interacts with cell membrane phospholipids, inhibits cytochrome c oxidase, and induces apoptosis-like cell death in Leishmania parasites. It also modulates host immune responses.
SATRIC is a combination of sulfathiazole, sulfacetamide, and sulfabenzamide, which are sulfonamide antibiotics. They competitively inhibit dihydropteroate synthase, blocking folate synthesis in susceptible bacteria.
60 mg/kg body weight per day (2.5 mg/kg per hour) by intravenous infusion over 6 hours, up to a maximum of 150 mg/day, for 21 days.
No standard dosing information available for SATRIC.
None Documented
None Documented
Terminal elimination half-life is approximately 16-21 days in adults; may be longer in severe hepatic impairment.
3-5 hours in healthy adults; prolonged to 6-8 hours in renal impairment (CrCl < 30 mL/min)
Primarily renal (over 90% as unchanged drug); fecal excretion is minimal (<5%).
Renal: 70% unchanged; fecal: 20%; biliary: 10%
Category C
Category C
Antiprotozoal
Antiprotozoal, Antibiotic